Report Highlights
The global market for nucleic acid aptamers reached $340.5 million in 2014. This market should grow to about $610.3 million in 2015 and about $5.4 billion in 2019, with a compound annual growth rate (CAGR) of 73.5% from 2014 to 2019.
Report Includes
- An overview of the specific applications for nucleic acid aptamers for therapeutic and diagnostic purposes, with a focus on applications judged to be commercially viable rather than enabling of basic research
- Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2019
- Identification of emerging technology growth opportunities in aptamer use as adjuvants for siRNA delivery, vaccines, and antisense technologies
- Examination of high growth and market potential segments of the industry, and new and established companies in the arena
- Comprehensive company profiles of major players in the industry.
Report Scope
This research report presents an in-depth analysis of the global nucleic acid aptamer market by technologies, applications and geographic regional markets. It includes key technologies involved, analyzes the capabilities and characteristics of aptamers in comparison with antibodies and lists specific areas where aptamers could find application. The evolving trends and technological developments in the field of aptamers have been studied in detail.
Special emphasis will be given to collaborative efforts, research innovations and investment clinical trials conducted. Patents will be discussed as well. This study also analyzes the aptamer-based drugs that have been developed or are in the pipeline for the treatment of various diseases. Impact analysis of the key drivers and factors affecting or influencing the growth of this market is also included.
The market for aptamer technologies is further categorized into enabling technology, diagnostic sensors and therapeutics. Enabling technology consists of SELEX technology, modified oligonucleotides, next-generation sequencing, nanoparticles and quantum dot labels, surface plasmon resonance and biolayer interferometry and bioinformatics. In terms of application the market is classified into diagnostics, therapeutics, research, biosensors, biomarker discovery and others.
Furthermore, diagnostics-based aptamers are used in environmental monitoring and food and water safety. They are also used for developing aptasensors for sensing small molecules and pathogens. Aptamers also find application in human clinical diagnostic assays for diagnosing diseases such as cancer, infectious diseases and other immunological diseases.
Aptamers are used in therapeutics and research as drug delivery vehicles in cancer, as a modifier of surgical implants and in bioseparation processes. Research areas include flow cytometry, mass spectrometry and Western blotting; they are also used as reagents and assays and as biosensors and biomarker molecules.
The market is segmented by regions into North America, Europe, Asia-Pacific and ROW. Companies profiled in this report include Ophthotech Corp., Alimera Sciences, AM Biotechnologies LLC, Alnylam Pharmaceuticals, Noxxon, Rina Gmbh, Regado Biosciences, Base Pair Biotechnologies Inc., Aptamer Sciences Inc., Aptasol (Aptamer Solutions) Ltd, Isis Pharmaceuticals, Neoventures Biotechnology Inc., Mitsui & Co. (U.S.A.) Inc., Quest Diagnostics, SomaLogic Inc. and Sumitomo Bakelite Co. Ltd.
Analyst Credentials
Yojana Jeevane has more than four years of experience in market intelligence and business research. She has experience in the healthcare domain with respect to medical devices, the life sciences market, and in the chemical domain. She has frequently delivered research services that contain strategic recommendations and top business strategies to help market players make strategic decision. She holds an MBA in Marketing.
Related Reports
Global Biochip Markets: Microarrays and Lab-on-a-Chip
The global biochip products market reached $3.3 billion in 2012. This market is expected to grow to nearly $3.9 billion in 2013 and $14.4 billion in 2018 at a compound annual growth rate (CAGR) of 30% for the five-year period 2013 to 2018.
Molecular Diagnostics: Technologies and Global Markets
In 2012, the global DNA diagnostics market was valued at $17.3 billion. The total market is projected to reach $20.1 billion in 2013 and nearly $36.5 billion by 2018, increasing at a compound annual growth rate (CAGR) of 12.6% from 2013 through 2018.
Antibody Drugs: Technologies and Global Markets
The global market for therapeutic monoclonal antibodies (mAbs) was estimated at $44.6 billion in 2011. With the rollout of at least eight new therapeutic mAb products and expanded indications for existing products expected during the forecast period, the global mAb market is expected to rise at a compound annual growth rate (CAGR) of 5.3% to nearly $58 billion in 2016.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Separation Systems for Commercial Biotechnology
The global market for bioseparation systems is expected to grow from $32.5 billion in 2025 and is projected to reach $45.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.8% during the forecast period of 2025 to 2030.
Biomarker Deals: Terms Value and Trends 2019-2025
This report provides an analysis of strategic transactions encompassing licensing, acquisitions and collaborations in the global biomarker market. It focuses on deals executed between 2019 and 2025, providing a retrospective assessment of deal-making activity to identify emerging trends, investment behaviors and strategic priorities in the biomarker landscape.
mRNA: Therapeutics and Global Markets
The global market for mRNA therapeutics was valued at $7.71 billion in 2025 and is forecast to remain stable or slightly decline to $7.69 billion by the end of 2030, at a compound annual growth rate (CAGR) of -0.04% during the forecast period of 2025 to 2030.
The Chinese Market for DNA Sequencing
The Chinese DNA sequencing market is expected to grow from $1.2 billion in 2025 and is projected to reach $3.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 21.5% during the forecast period of 2025 to 2030.
Molecular Diagnostics: Technologies and Global Markets
The global market for molecular diagnostics is expected to grow from $23 billion in 2025 and is projected to reach $42.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.1% during the forecast period of 2025 to 2030.
Report Highlights
The global aptamer market was valued at $40 million in 2011 and should reach nearly $99 million in 2012. Total market value is expected to reach nearly $3.7 billion in 2017 with a five-year compound annual growth rate (CAGR) of 106.3%.
Report Includes
- An overview of the specific applications for nucleic acid aptamers for therapeutic and diagnostic purposes, with a focus on applications judged to be commercially viable rather than enabling of basic research
- Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Identification of emerging technology growth opportunities in aptamer use as adjuvants for siRNA delivery, vaccines, and antisense technologies
- Examination of high growth and market potential segments of the industry, and new and established companies in the arena
- Comprehensive company profiles of major players in the industry.
Report Highlights
-
The global market for aptamers is poised for significant new market entrants in the near future. In 2009 this market was valued at $10 million. By 2014, this market is estimated to be worth $1.9 billion, a compound annual growth rate (CAGR) of nearly 68%.
-
Aptamer therapeutic markets were valued at $10 million in 2009 and should increase at a 55% compound annual growth rate (CAGR) to $1.2 billion in 2014.
-
Aptamer diagnostic markets were worth $26 million in 2010 and are expected to increase in value to $659 million in 2014, a compound annual growth rate (CAGR) of 124%.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More